Executive Summary: Key Legal and Evidentiary Issues

• Scope of Bayer’s preliminary motion to partially dismiss the class action and annul the prior authorization order under articles 51 and 588 C.p.c.
• Threshold for striking portions of a product-liability class action at a preliminary stage where complex and contested expert evidence on medical causation remains to be tested at trial.
• Extent to which plaintiffs’ expert reports on Essure’s potential to cause infections, menorrhagia and autoimmune symptoms are sufficient to maintain these alleged harms as viable common issues.
• Interaction between “generic causation” (capacity of the device to cause harm) and “specific causation” (individual proof of link between device and each member’s injury) in the context of warnings and safety-defect claims.
• Pleading and evidentiary foundation required to keep punitive damages in play under article 49 of the Quebec Charter for alleged intentional or reckless failure to warn.
• Use and limits of article 588 C.p.c. to revisit an authorization judgment based on later-filed expert evidence, versus leaving issues of causation, common questions and damages structure to the trial judge.

Background and facts of the Essure class action

The case arises from a Quebec class action brought by representative plaintiff Joan Letarte against Bayer Inc. and Bayer Healthcare LLC concerning the Essure permanent contraceptive implant. The class consists of all Quebec women who allegedly suffered health problems associated with the Essure device, which was manufactured or distributed by Bayer. [4] The Essure system is described as a permanent female contraception method intended to cause bilateral occlusion of the fallopian tubes. Micro-implants composed of metal spirals (nickel, steel, nitinol and PET fibers) are inserted into the fallopian tubes via hysteroscope, where tissue growth is expected to block the tubes. [16]–[17] The plaintiff alleges that Essure increases the risk of several adverse medical conditions: urinary tract infections, perforated organs, implant migration, pelvic pain, menorrhagia and autoimmune symptoms (collectively referred to as the “Conditions médicales reprochées”). [5]–[7] She further contends that Bayer failed to adequately disclose the existence and magnitude of these risks to patients and physicians. [6] The alleged wrongdoing is framed both as a product safety-defect case under article 1469 C.c.Q. and as a failure-to-warn case in which insufficient or delayed information about serious risks deprived women and their doctors of an informed choice.

The prior authorization judgment and common questions

On 20 March 2019, Justice Chantal Lamarche of the Superior Court authorized the class action on behalf of the proposed group of Quebec women. [4] In doing so, she certified five common questions to be addressed collectively. The first and central question is whether Essure causes, exacerbates or contributes to a risk of the listed medical conditions. Only if that question is answered affirmatively can the court proceed to address whether Bayer committed a fault by failing to warn or by the way it marketed, packaged, promoted, advertised, distributed, labelled and sold Essure, and then the entitlement of class members to compensatory and punitive damages. [5] The authorization judgment thus establishes a two-step structure: the class must first establish “generic” causation between the device and the alleged conditions; only then can it move to issues of fault, damages and punitive damages on a collective or individual basis.

The defendants’ theories and motion for partial dismissal

Following authorization, the representative plaintiff filed her originating application in August 2019, repeating the central allegation that Essure increases the risk of the contested conditions and that Bayer’s information to the market was deficient. [6] Bayer then brought a substantial preliminary motion seeking three forms of relief. First, it asked for partial dismissal of the action under article 51 C.p.c. on the basis that the causes of action tied to urinary tract infections, menorrhagia and autoimmune symptoms were “manifestly ill-founded”. Bayer argued that none of the experts, including those retained by the plaintiff, truly asserted that these conditions are a logical, immediate and direct consequence of the Essure implant. [8], [11.1] Second, Bayer sought partial dismissal of the punitive damages claim, also under article 51 C.p.c., on the basis that there were no sufficient allegations or evidence of intentional or grossly negligent conduct that would support punitive damages under the Quebec Charter. [11.2], [60]–[64] Third, Bayer invoked article 588 C.p.c. and asked the court to annul the authorization judgment, asserting that “new facts” emerging from the parties’ extensive expert evidence showed that the conditions for authorization, particularly the existence of common issues on causation and compensatory damages, were no longer met. [9]–[11.3], [71] The core of Bayer’s argument was that the plaintiff’s own experts had effectively conceded that causation must be analyzed individually for each class member and for each alleged condition, such that questions 1 and 4 (causation and compensatory damages) could not meaningfully be treated as common questions. [9], [70]–[82]

Legal framework on preliminary dismissal for abuse

Justice Sheehan begins by reviewing the principles governing preliminary dismissal motions under article 51 C.p.c., which applies equally in class actions where the manifestly ill-founded nature of a claim is shared by a significant portion of the class. [12]–[13] The court recalls that while the judiciary has tools to terminate actions that are clearly doomed to fail as part of sound judicial resource management, the consequences of a preliminary dismissal are serious and such powers must be exercised sparingly, only when the recourse is “necessarily voué à l’échec” in a clear and obvious case. [13.1]–[13.3] The judge stresses that a dismissal for “abuse” because a pleading is manifestly ill-founded, frivolous or dilatory requires “la plus grande prudence” and must not be used as a shortcut to obtain an early merits judgment on the file. [13.3]–[15] The court may look at the whole record, including pleadings, exhibits and examinations, but should not conduct a “trial within the trial” or prejudge complex and contested evidentiary debates, particularly when expert evidence is voluminous and has not been tested by cross-examination. [13.5], [15], [34]–[35], [47]–[50] The judge emphasizes that intent is not required to find abuse, but that if the situation is not clearly hopeless, contested factual or mixed fact-law questions must be left for the trial judge to resolve after hearing complete evidence. [13.7]–[13.9], [49]–[52]

Causation and the Essure-related medical conditions

On the substantive product-liability framework, the judgment reiterates that plaintiffs must prove three elements: a safety defect in the product, a compensable injury, and a causal link between the defect and the injury. [19] The plaintiff’s theory heavily relies on the absence of adequate warnings as a safety defect under article 1469 C.c.Q., which applies even to products without classic “vices” but that carry inherent dangers requiring disclosure. [21]–[22] Drawing on Court of Appeal authority, the judge notes that manufacturers have a stringent duty to provide adequate information on dangers so that users can make an informed choice and know how to protect themselves; this duty is particularly intense for products ingested or implanted in the body, where potential harm is serious or not negligible. [22]–[24] The judgment also distinguishes between “generic causation” (whether the product has the capacity to produce the alleged harmful effects) and “specific causation” (the link between the product and each individual’s injury). [24]–[25] Generic causation can be proven by scientific or technical expert evidence (epidemiology, toxicology, statistics) under the usual civil balance-of-probabilities standard, and in the case of drugs or medical devices, even documented serious adverse events occurring in temporal association with use may trigger a duty to warn, under a precautionary approach, even if full causation has not yet been scientifically established. [25]–[28] The plaintiff and Bayer had both filed extensive expert evidence. The plaintiff relied on reports by Dr. James Wheeler (obstetrics-gynaecology), Dr. Ernest Chiodo (toxicology) and Louis-Paul Marin (regulatory), plus reply reports by each. [31], [33] Bayer tendered expert opinions from Drs. Eiselstein (metallurgy/corrosion), Le Lorier (epidemiology), Marchand (neuroscience), Waddell (obstetrics-gynaecology) and Boyer (regulatory). [32] The combined expert record spanned thousands of pages and no expert had yet been examined or cross-examined. [34]

Evidence on urinary infections, menorrhagia and autoimmune symptoms

Bayer targeted three categories of alleged harm—urinary tract infections, menorrhagia and autoimmune symptoms—as being unsupported by the plaintiff’s own experts. It pointed out that these conditions are common in women and can stem from many physiological causes, and emphasized that epidemiologic data did not show a higher incidence of urinary infections among Essure users compared to the general population or women who had tubal ligation. [37] Bayer also noted that Dr. Wheeler himself described the causal link between Essure and urinary infections as weak or even improbable. [37], [40] Justice Sheehan accepts that the plaintiff’s experts acknowledge the causal picture is complex and that some links are tenuous, but stresses that the record still contains evidence that could support the plaintiff’s theory at trial. Dr. Wheeler, for instance, indicates that the link between Essure and urinary infections is not impossible, that the device may cause infections in some patients, and references a study reporting urinary-tract-infection prevalence of 26% among Essure recipients, which dropped significantly after device removal. [38] Dr. Wheeler also opines that Essure can be a contributory factor in abnormal uterine bleeding, including menorrhagia, citing adverse event reports, the number of women who chose hysterectomy to end their symptoms, and studies describing abnormal bleeding post-implantation sometimes requiring hysterectomy. [39] On autoimmune symptoms, he acknowledges that reported cases are rare but emphasizes that rarity does not diminish the importance of complications for affected individuals, and he cites a 2016 study expressing clear concern about immune complications related to Essure. [40] In parallel, Dr. Chiodo explains how metal ion release from the device, including nickel, may provoke autoimmune or hypersensitivity reactions and relies on literature suggesting a possible association between Essure and autoimmune symptoms. [40]–[41] Drawing on pharmacovigilance databases, Mr. Marin concludes that the volume of clinical reports related to Essure is not reflected in the information provided to patients and physicians. [40]–[41] The judge concludes that while the plaintiff’s causation case regarding these three conditions may be difficult, there is nonetheless “une certaine preuve” supporting her causal syllogism, and it is not for a preliminary-motion judge to weigh conflicting expert reports and declare the case doomed. [41]–[47]

Evidence on pelvic pain, perforation and migration

The record is even stronger with respect to pelvic pain and device perforation or migration. Dr. Wheeler notes that women with Essure implants report pelvic pain at various times, including in cases where the initial placement was uneventful, and that many see improvement after device removal. He describes Essure as a contributory cause of pelvic pain in many women and probably the primary cause for some. [42] Supporting this, Dr. Chiodo discusses how degradation of the tin solder in the implant can provoke inflammatory tissue responses capable of explaining pelvic pain and menorrhagia. [42]–[43] Justice Lamarche in the earlier authorization decision had also cited three studies indicating possible pain linked to Essure. [43] On migration and perforation, Dr. Wheeler concludes that the causal link between Essure and mispositioning is the strongest among all alleged conditions, and he relies on a 2013 study reporting perforation cases. [45] On the defence side, Dr. Waddell and Dr. Le Lorier insist that pelvic pain causation is extremely difficult to analyze due to multiple potential sources, and that epidemiologic data do not show increased pelvic pain among Essure users versus tubal-ligation patients. [44] Yet the authorization judge had already found that the appropriate comparator group might be the general population rather than just tubal-ligation patients, and Dr. Wheeler cites a study suggesting that while Essure and laparoscopic sterilization have similar unintended pregnancy risk, Essure carries a tenfold higher risk of requiring re-operation. [44] Overall, Justice Sheehan finds that this expert landscape reveals a genuine, contested factual dispute on generic causation that must be resolved at trial, not swept aside on a preliminary motion.

Rejection of the partial dismissal on causation grounds

In light of the above, the court declines to strike the plaintiff’s claims concerning urinary infections, menorrhagia and autoimmune symptoms. Justice Sheehan stresses that a motion under article 51 C.p.c. is not the proper vehicle for a detailed merits review of complex expert causation evidence. [48]–[51] The court notes that expert evidence is not necessarily the entire causation proof; testimony from patients and presumptions of fact may also play an important role, especially where there is temporal concurrence between device use and symptom onset, and improvement upon device removal. [51]–[52] The court also rejects Bayer’s reliance on foreign decisions from Australia (Turner v. Bayer Australia Ltd.) and France that found no safety defect in Essure, pointing out that those judgments were rendered after full trials with extensive patient and expert testimony and have no res judicata effect in Quebec. [53]–[56] At this stage, the issue remains a mixed question of fact and law requiring a full evidentiary record. Since it cannot be said that further examination would be superfluous, the court holds that the action is not manifestly ill-founded and refuses to grant partial dismissal. [57]–[58]

Punitive damages and alleged intentional misconduct

Bayer also sought to strike the punitive damages component of the class action, arguing that the pleadings and evidence contained no sufficient basis to allege an “atteinte illicite et intentionnelle” to a right protected by the Quebec Charter, as required for punitive damages under article 49. [61]–[64] The court reviews the applicable principles: punitive damages are only available if provided by law, and for Charter-based claims, there must be either a will to cause the consequences of the wrongful conduct or action in full knowledge of the immediate or highly probable consequences. [62]–[63] Courts will readily reject punitive damage claims at an early stage if pleadings lack factual allegations of intentional violations, bad faith, gross negligence, or if defendants have quickly remedied problems. [64] At the same time, because punitive damages depend on an overall assessment of the defendant’s conduct, it may be premature to rule them out before trial; a specific allegation of intentional or reckless conduct tied to the asserted fault can suffice if the application as a whole permits the court to infer illicit and intentional behaviour. [65] In this case, the plaintiff’s originating application alleges that Bayer commercialized Essure despite knowledge of serious health risks, withheld complete information, and persisted in denying adverse effects. [66] Notably, paragraph 37w expressly pleads Bayer’s “insouciance téméraire”, and paragraph 37q alleges that Bayer knew or ought to have known the risks associated with Essure. [67] The regulatory expert report by Mr. Marin is identified as potentially supporting these allegations. [68] Given these pleadings and the still-developing evidentiary record, Justice Sheehan finds it would be imprudent to dismiss the punitive damages claim at this early stage and refuses to do so. [69]

Framework for revising or annulling the authorization judgment

On the second branch of Bayer’s motion, the court examines article 588 C.p.c., which allows the Superior Court to review or annul an authorization judgment “en tout temps” if it considers that the conditions relating to common questions or group composition are no longer met. [71]–[73] Drawing on doctrine and case law, Justice Sheehan stresses several constraints. The power is limited to the first and third criteria under article 575 C.p.c. (existence of identical, similar or related questions of law or fact, and appropriateness of the class procedure as opposed to mandates or joinder of actions). [73.2] It is meant to prevent a class proceeding from being carried through to final judgment when, during the case, the conditions for the class mechanism genuinely cease to exist; it must not be used as an indirect appeal of the authorization ruling. [73.3] Review must be based on new facts arising during the proceedings that were not known at the authorization stage. [73.3] Importantly, the judge hearing an article-588 motion is not there to answer the common questions; that role lies with the trial judge. Their role is only to assess whether, at some point, there still exist questions of law or fact that are identical, similar or related among members. [73.4] The court notes that the same prudence required when considering preliminary dismissal applies to requests to annul an authorization, given the social objectives of class proceedings—access to justice, behaviour modification and judicial economy. [74]–[75] Class actions make justice accessible for some plaintiffs only through aggregation and avoid duplication in fact-finding and legal analysis; these purposes argue against lightly revisiting authorization.

Application of article 588 C.p.c. to Bayer’s evidence

Justice Sheehan observes that Bayer’s arguments about lack of causation and lack of common issues are not meaningfully new; they were already raised and considered during the authorization hearing based on sworn statements from Dr. Waddell that are essentially restated in his later expert report. [78]–[79] As a general rule, defence expert reports filed after authorization do not constitute “new facts” justifying revision, especially when they bolster arguments already advanced. [79] The court recognizes that in some cases, post-authorization interrogations of class members yielding clear admissions can qualify as new facts, but here, the named plaintiff was examined before authorization, so her testimony is not new. [80] Bayer therefore places its reliance on the combined post-authorization expert record, contending that all experts—including those retained by the plaintiff—now demonstrate that causation must be assessed on an individual basis and that compensatory damages are inherently individual, undermining questions 1 and 4 as common issues. [81] Justice Sheehan holds that even if Bayer’s reading of the expert evidence were accepted, it would not justify annulling authorization. The trial judge can ultimately decide that proof of causation for some or all alleged conditions must proceed case by case, order individual-rather-than-collective recovery, or reclassify causation as an individual question while still adjudicating other issues collectively. [82]–[83] The Court of Appeal has recognized that in some class actions, causation can be proven collectively, while in others users may have to make individual causation showings. [84] Moreover, the presence of individual issues regarding causation or damages does not displace the central common question—whether Bayer should have warned patients and their doctors about Essure’s risks. [85] The trial judge may also use categories to structure damages and rely on presumptions of fact to assess harm. [85]–[86] Ultimately, the judge concludes that there remains a common question of significant importance—whether Essure increases the risk of the alleged conditions and whether Bayer’s warnings and conduct were adequate—and that answering this question at trial will advance the litigation in a non-negligible way for all class members. [75]–[77], [86] Article 588 C.p.c. therefore does not justify revisiting the authorization judgment.

Outcome and implications for the parties

In the result, the Superior Court of Quebec rejects Bayer’s entire motion. Justice Sheehan refuses to partially dismiss the action in respect of urinary infections, menorrhagia, autoimmune symptoms or punitive damages, and declines to annul or revise the 2019 authorization judgment. [58], [69], [88] The court also extends the time limit for preparing the file and inscribing it for trial to 1 May 2026, with costs to follow the eventual outcome of the proceedings. [89]–[90] This decision leaves the class action intact and allows the plaintiff, Joan Letarte, to proceed as representative of the certified group against Bayer on all alleged conditions and on both compensatory and punitive damages theories. At this interlocutory stage, there is no monetary judgment: the successful party in this motion is the plaintiff, but the court has not awarded any specific amount for damages, costs or other monetary relief, and the total monetary award ordered in favour of the successful party in this decision is therefore undetermined (effectively zero at this point).